-
Deutsche Bank made a number of updates in a research report published today.
Monday, July 18, 2011 - 8:28am | 159Valeant Pharmaceuticals (NYSE: VRX) had its rating reiterated at Buy. At the same time, its price target was raised from $62 to $64. On Friday, VRX added 4.54% to its value to finish the week at $55. KapStone Paper (NYSE: KS) had its rating reiterated at Hold. On Friday, KS added 0.3% to its value...
-
Deutsche Bank Provides Color on Pharmaceuticals
Monday, July 18, 2011 - 8:15am | 138Deutsche Bank provided color on the pharmaceuticals sector. In a research report published today, Deutsche Bank named Pfizer (NYSE: PFE), Merck (NYSE: MRK) and Bristol Myers Squibb (NYSE: BMY), all Buy-rated, as its top picks. On Friday, BMY lost 0.45% of its value to finish the day at $28.97. Its...
-
Citi Comments on Eli Lilly
Monday, July 18, 2011 - 8:12am | 138Citi has put out a report on Eli Lilly (NYSE: LLY). In the report, Citi commented that, "Our 2Q11 EPS is $1.20 (+5% YOY), above the Street's $1.17. We model 2Q11 revenue of $6.05B (+5%), above the Street's $5.99B. We project US and international sales of $3.29B (+1%) and $2.76B (+11%, assuming a...
-
Forest Laboratories Will Nominate 10 Candidates for Company's Board of Directors
Monday, July 18, 2011 - 8:12am | 40Forest Laboratories, Inc. (NYSE: FRX) today announced that it will nominate a slate of ten candidates for election to the Company's Board of Directors at the 2011 Annual Meeting of Shareholders on August 18, 2011.
-
Merck's ISENTRESS in Combination Therapy Demonstrated Efficacy in a Phase II Study Extending to Nearly Five Years in Previously Untreated Adults with HIV-1
Monday, July 18, 2011 - 8:06am | 216Merck (NYSE: MRK) today announced final results from a Phase II clinical study, extending out to 240 weeks, of its integrase inhibitor ISENTRESS® (raltegravir) Tablets in combination therapy in previously untreated (treatment-naïve) adult HIV-1-infected patients. The regimen containing ISENTRESS...
-
Benzinga's Top Pre-Market Losers
Monday, July 18, 2011 - 8:06am | 113Abbott Laboratories (NYSE: ABT) dipped 5.34% to $50.21 in the pre-market session. ABT is scheduled to report its quarterly results on July 20. News Corporation (NASDAQ: NWSA) dropped 4.16% to $14.99 in the pre-market trading. UK police arrested NWSA's former CEO Rebekah Brooks. Hewlett-Packard...
-
Hearing Positive Twitter Chatter on Amarin
Monday, July 18, 2011 - 7:39am | 34@markflowchatter reports that Amarin (NASDAQ: AMRN) will be meeting with Lazard on Tuesday, and positive news could emerge.
-
A Peek Into The Market Before The Trading Starts
Monday, July 18, 2011 - 7:24am | 345Pre-open movers US stock futures are lower this morning. Futures on the Dow Jones Industrial Average dropped 87 points to 12,365.00 and futures on the S&P 500 stock index fell 10 points to 1,304.50. Nasdaq 100 futures dipped 19.75 points to 2,335.75. A Peek Into Global Markets Asian...
-
Pre-Market Losers
Monday, July 18, 2011 - 7:24am | 126Abbott Laboratories (NYSE: ABT) is trading down over 5.30%, near $50.20. News Corp (NASDAQ: NWS)(NASDAQ: NWSA) is trading down over 5%, near $15.25 after former CEO Brooks was arrested. LinkedIn (NYSE: LNKD) is trading down over 4%, near $105.50 after the company's rating was cut at JP Morgan to...
-
Eli Lilly Announces New Data Showed Minimal Potential for Drug Interaction Between Cholesterol Drug LIVALO and a Common Antiretroviral Therapy
Monday, July 18, 2011 - 7:22am | 139Kowa Pharmaceuticals America, Inc. and Eli Lilly and Company (NYSE: LLY) earlier today released new study results that investigated the potential interaction of cholesterol drug LIVALO (pitavastatin) 4 mg in healthy volunteers taking the protease inhibitor combination lopinavir/ritonavir, a fixed...
-
Jefferies Raises PT On Eli Lilly To $34
Monday, July 18, 2011 - 7:14am | 27Jefferies & Company has raised the price target on Eli Lilly (NYSE: LLY) from $33 to $34 and maintains its Hold rating.
-
Jefferies Lowers PT On Bristol-Myers Squibb To $27
Monday, July 18, 2011 - 7:12am | 27Jefferies & Company has lowered the price target on Bristol-Myers Squibb (NYSE: BMY) from $28 to $27 and maintains its Hold rating.
-
Shire's Lialda Now Approved in U.S. for Maintenance of Remission of Ulcerative Colitis
Monday, July 18, 2011 - 7:02am | 283Shire plc (NASDAQ: SHPGY) today announced that the U.S. Food and Drug Administration (FDA) approved Lialda® (mesalamine) Delayed Release Tablets for the maintenance of remission in patients with ulcerative colitis. This approval is based on results from a six-month study demonstrating the safety...
-
Deutsche Bank Raises PT On Valeant Pharmaceuticals To $64
Monday, July 18, 2011 - 6:28am | 27Deutsche Bank has raised the price target on Valeant Pharmaceuticals (NYSE: VRX) from $62 to $64 and maintains its Buy rating.
-
Amarin to Meet With Lazard on Monday, July 18 -Twitter
Saturday, July 16, 2011 - 5:56pm | 79Subsequent to reports that MKM Partners upgraded Amarin (NASDAQ: AMRN) to a Buy rating and that Amarin also hired Lazard to explore a potential sale of the company, @markflowchatter reports that Amarin (NASDAQ: AMRN) will be meeting with Lazard this upcoming Monday, July 18th.